Tanshinone IIA potassium sulfonate used for preparing medicine for preventing and treating cerebral ischemia and cerebral anoxia and myocardial ischemia and myocardio anoxia

A technology of tanshinone and potassium sulfonate, applied in the field of preparation of medicaments for preventing and treating myocardial ischemia hypoxia and cerebral ischemia hypoxia by tanshinone IIA potassium sulfonate

Inactive Publication Date: 2007-11-14
刘小虎
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, also do not see any report about potassium tanshinone IIA sulfonate, and be used for preventing and treating the report of myocardial ischemia hypoxia, cerebral ischemia hypoxia and related diseases with tanshinone IIA potassium sulfonate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tanshinone IIA potassium sulfonate used for preparing medicine for preventing and treating cerebral ischemia and cerebral anoxia and myocardial ischemia and myocardio anoxia
  • Tanshinone IIA potassium sulfonate used for preparing medicine for preventing and treating cerebral ischemia and cerebral anoxia and myocardial ischemia and myocardio anoxia
  • Tanshinone IIA potassium sulfonate used for preparing medicine for preventing and treating cerebral ischemia and cerebral anoxia and myocardial ischemia and myocardio anoxia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1: Extraction, separation and purification of Tanshinone IIA in Salvia miltiorrhiza

[0042]Dried Salvia miltiorrhiza 1kg, extracted with 95% ethanol for 3 times, each time for 24 hours, the extract was concentrated under reduced pressure to 500mL, then added 500mL of water, extracted four times with 1000mL chloroform, the extract was concentrated under reduced pressure, and the column layer Analysis and separation, the silica gel is 100-200 mesh, the eluent is petroleum ether / ethyl acetate mixed solution containing 1%-10% ethyl acetate, and gradient elution is carried out. About 0.85g of tanshinone IIA can be obtained.

Embodiment 2

[0043] The synthesis of embodiment 2 Tanshinone IIA potassium sulfonate

[0044] The synthesis process of potassium tanshinone IIA sulfonate: take 50 grams of tanshinone IIA (purity above 20%), add 200 milliliters of acetic anhydride, place it in a three-necked bottle, add 100 milliliters of concentrated sulfuric acid dropwise at 10-15 °C under stirring- The mixed solution of glacial acetic acid (1:1, V / V), after the dropwise addition, was stirred at room temperature for one hour, then the reaction solution was slowly poured into an equal volume of distilled water, and 1 liter of saturated potassium chloride ( Chemically pure) aqueous solution, that is, crude potassium tanshinone IIA sulfonate is precipitated, centrifuged, the precipitate is washed twice with saturated potassium chloride solution, and then washed once with an appropriate amount of water to make the pH of the solid matter = 5.6, and the filtered solid matter is placed on a water bath Evaporate to dryness, reflu...

Embodiment 3

[0045] Embodiment 3: Toxicological test of potassium tanshinone IIA sulfonate

[0046] Acute toxicity test in mice: The animals used in the test were healthy male Kunming mice. Tested by intravenous method. The dosage is 100mg / kg (the maximum amount has been reached). After the experiment, the mice were fed and observed for 7 days under the condition of free drinking and eating at 20±1°C, and the survival and appearance of the mice were observed.

[0047] Results: After administration, all the mice survived, and the appearance and behavior of the survivors were normal, and LD could not be detected. 50 . It is determined that potassium tanshinone IIA sulfonate has no toxic and side effects within the range of effective therapeutic dose and can be taken for a long time.

[0048] 30-day toxicity test on mice: The animals used in the test were healthy male Kunming mice. Tested by intravenous method. The dosage is 50mg / kg / day for 30 consecutive days. The test showed that the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention relates to synthetic craft, preparation and new medicine function of a new water-solubility ramification of tanshinone iia: tanshinone iia sulfonic acid kalium ( potassium tanshinone iia sulfonate, PTS). The invention concretely relates to the pharmic application of tanshinone iia sulfonic acid kalium in prevention and treatment of myocardial ischemia and anoxia, cerebral ischemia and anoxia, microcirculation ameliorating, memory enhancing and corelated disease(cerebralthrombosis, acute cerebral ischemia, coronary heart disease, angina pectoris, myocardial infarction0.

Description

technical field [0001] The invention relates to a synthesis process, preparation and new medical application of a new water-soluble derivative of tanshinone IIA, potassium tanshinone IIA sulfonate (potassium tanshinone IIAsulfonate, PTS). Specifically designed potassium tanshinone IIA sulfonate is used for the preparation of prevention and treatment of myocardial ischemia and hypoxia, cerebral ischemia and hypoxia, improving microcirculation, enhancing memory and related diseases (cerebral thrombosis, acute cerebral ischemia, coronary heart disease, angina pectoris, myocardial infarction ) use of the drug. technical background [0002] Cerebrovascular disease is a general term for cerebrovascular diseases caused by various etiologies. Cerebrovascular disease, heart disease, and malignant tumors constitute the three leading causes of death in many countries. [0003] Cerebral ischemia is caused by insufficient blood supply or functional cessation of the brain due to various...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07J73/00A61K31/58A61P9/10A61P25/28
Inventor 刘小虎
Owner 刘小虎
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap